HALIX Appoints Dr. Lutz Hilbrich as New Chief Executive Officer

Halix B.V. Netherlands United Kingdom United States of America

is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca's COVID-19 vaccine. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000 L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group.

Media Contact:
Kassandra Barbetsea
Marketing manager
HALIX B.V.
Email: [e-mail]
Phone: [phone]

 

View original content:https://www.prnewswire.co.uk/news-releases/halix-appoints-dr-lutz-hilbrich-as-new-chief-executive-officer-302253093.html